SELLAS Life Sciences (SLS) Net Cash Flow (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Net Cash Flow for 17 consecutive years, with $35.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 143.61% year-over-year to $35.4 million; the TTM figure through Mar 2026 stood at $78.7 million (up 688.77% YoY), while the FY2025 annual figure was $57.9 million, up 409.83% from the prior year.
• Net Cash Flow advanced to $35.4 million in Q1 2026 per SLS's latest filing, from $27.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $35.4 million in Q1 2026 and bottomed at -$9.8 million in Q3 2023.
• Historically, Net Cash Flow has averaged $5.5 million across 5 years, with a median of -$1.4 million in 2023.
• Annual changes were most pronounced in 2022 — Net Cash Flow surged 814.81% — and 2024, when it plunged 396.53%.
• SELLAS Life Sciences' Net Cash Flow stood at -$4.2 million in 2022, then jumped by 65.92% to -$1.4 million in 2023, then tumbled by 396.53% to -$7.1 million in 2024, then jumped by 484.35% to $27.5 million in 2025, then rose by 28.72% to $35.4 million in 2026.
• Business Quant data shows SLS's Net Cash Flow at $35.4 million in Q1 2026, $27.5 million in Q4 2025, and $19.0 million in Q3 2025.